Lupin shares rose on Friday after the pharma major reported a robust 73% YoY surge in Q2 FY26 PAT to Rs 1,485 crore, driven by strong sales growth, margin expansion, and operational efficiency. Revenue jumped 24% YoY to Rs 6,831 crore, while EBITDA soared 76%.